Press release
Idiopathic Hypersomnia Treatment Market Propelled by Rising Sleep Disorder Diagnosis and Breakthrough CNS Therapies | Jazz Pharmaceuticals plc, Harmony Biosciences Holdings, Inc., AVADEL PHARMACEUTICALS PLC
Global idiopathic hypersomnia treatment market reached USD 1.5 Billion in 2024 and is expected to reach US$ 2.8 Billion by 2031, growing at a CAGR of 9% during the forecast period 2024-2031.Idiopathic Hypersomnia Treatment Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/idiopathic-hypersomnia-treatment-market?ophp
Idiopathic Hypersomnia is a rare neurological disorder marked by excessive daytime sleepiness despite adequate rest. The treatment market is expanding due to recent FDA-approved therapies (e.g., low-sodium oxybate), growing diagnosis rates, and rising demand for CNS-targeted sleep disorder drugs.
Idiopathic Hypersomnia Treatment Market Competitors Overview:
Jazz Pharmaceuticals plc, Harmony Biosciences Holdings, Inc., AVADEL PHARMACEUTICALS PLC, Zevra Therapeutics, Inc., Teva Pharmaceuticals USA, Inc., Mylan N.V., Hoffmann-La Roche Limited, BIOPROJET, Theranexus, Shionogi Inc. and among others.
Important Industry Updates of 2023, 2024 and 2025:
✅ In December 2024 - FDA approved olezarsen, marketed as Tryngolza, for adults with familial chylomicronemia syndrome (FCS) to reduce triglycerides as adjunct to diet. It's the first FDA-approved treatment for FCS, based on the Phase 3 Balance trial demonstrating ~57% TG reduction at six months
Cutaneous Lupus Erythematosus
✅ Late 2024 - early 2025 - Plozasiran (Arrowhead's ApoC‐III siRNA) completed a positive Phase 3 trial in FCS (~80% TG reduction) and plans regulatory filings; NDA accepted by FDA on January 17, 2025, with PDUFA target date: November 18, 2025
Methodology and Scope
The Idiopathic Hypersomnia Treatment Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/idiopathic-hypersomnia-treatment-market?ophp
Idiopathic Hypersomnia Treatment Market Segments Overview:
∎ By Treatment Type(Non-Stimulant Wake-Promoting Medications (Modafinil, Armodafinil, Solriamfetol, Pitolisant and Others), CNS Depressants(Xyrem , Xywav), Psychostimulants(Amphetamines, Methylphenidate, Others) and Others)
∎ By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Regional Overview for Idiopathic Hypersomnia Treatment Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=idiopathic-hypersomnia-treatment-market?ophp
The Report Covers:
➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.
People Also Ask:
➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Hypersomnia Treatment Market Propelled by Rising Sleep Disorder Diagnosis and Breakthrough CNS Therapies | Jazz Pharmaceuticals plc, Harmony Biosciences Holdings, Inc., AVADEL PHARMACEUTICALS PLC here
News-ID: 4119694 • Views: …
More Releases from DataM intelligence 4 Market Research LLP

United States Prime Editing and CRISPR Market 2025 | Growth Drivers, Key Players …
Market Size and Growth
Prime Editing and CRISPR Market is estimated to grow at a CAGR of 24.1% during the forecast period (2024-2031).
Key Development:
United States: Recent Industry Developments
✅ July 2025 - Prime Medicine announced an additional investment of up to $24 million from the Cystic Fibrosis Foundation to advance gene editing therapy targeting the G542X mutation, a prevalent cystic fibrosis-causing mutation with no current therapies.
✅ July 2025 - CRISPR…

United States Clinical Workflow Solutions Market 2025 | Growth Drivers, Market F …
Market Size and Growth
The Clinical Workflow Solutions Market size is growing at a high CAGR 12.3% during the forecast period (2023-2030).
Key Development:
United States: Recent Industry Developments
✅ In August 2025, Elation Health unveiled a significant AI expansion to its clinical-first platform, integrating native AI tools across all products at no additional cost. This enhancement aims to reduce administrative burdens and improve primary care workflows.
✅ In June 2025, Commure launched Commure Agents,…

United States Smart Robot Market 2025 | Growth Drivers, Market Forecast, Competi …
Market Size and Growth
The Global Smart Robot Market size is growing at a high CAGR during the forecast period (2024-2031).
Key Development:
United States: Recent Industry Developments
✅ In September 2025, ReWalk Robotics introduced an advanced lower-limb exoskeleton designed for stroke and spinal injury rehabilitation. This medical service robot aims to enhance mobility and independence for individuals with lower-limb disabilities, marking a significant advancement in healthcare robotics.
✅ In July 2025, Meta launched its…

United States Bio Active Protein Market 2025 | Growth Drivers, Market Forecast, …
Market Size and Growth
The Global "Bio Active Protein Market" is expected to grow at a CAGR during the forecast period 2024-2031
Key Development:
United States: Recent Industry Developments
✅ In September 2025, The Protein Brewery secured $35.6 million in Series B funding to scale its fungi-based bioactive protein production platform. The investment aims to accelerate the commercial launch of its sustainable protein ingredients in the U.S. and Singapore markets.
✅ In September 2025, Glanbia,…
More Releases for Idiopathic
Idiopathic Pulmonary Fibrosis Market Size & Share Analysis
The new report published by The Business Research Company, titled Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89…
Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Idiopathic Pulmonary Fibrosis Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…